- Home
- Pathology Industry
- Cancer Drug Market and Forecasts, May 2013
Industries
- Pathology (730)
- Drug and Medication (437)
- Managed Care (296)
- Water Distribution and Treatment (257)
- Tobacco (154)
-
- Healthcare (138)
- Medical Facility (94)
- Biotechnology (89)
- Drug Discovery and Development (85)
- Pharmaceutical (79)
- Energy & Environment (72)
- Biopharmaceutical (69)
- Cigarette > newspaper > liquor Stores (64)
- Skin Care Products (60)
- Genomics (56)
- Food (43)
- Diagnostics (42)
- Fruit and Vegetable (42)
- Biological Therapy (41)
- Metal and Mineral (41)
Top countries
- United States (1 632)
- India (322)
- World (319)
- Europe (202)
- Canada (176)
-
- China (153)
- United Kingdom (124)
- Australia (114)
- Georgia (70)
- Japan (55)
- Germany (49)
- South Korea (31)
- France (27)
- Africa (27)
- Russian Federation (25)
- South Africa (24)
- Malaysia (24)
- Spain (24)
- Netherlands (23)
- Asia (23)
Publication dates
All regions
-
- Algeria (2)
- Botswana (1)
- Chad (1)
- Congo, Democratic Republic Of (1)
- Egypt (5)
- Ethiopia (2)
- Gambia (3)
- Ghana (8)
- Kenya (6)
- Libyan Arab Jamahiriya (1)
- Malawi (1)
- Mauritius (1)
- Morocco (1)
- Mozambique (1)
- Namibia (2)
- Nigeria (11)
- Rwanda (4)
- Sierra Leone (2)
- Somalia (3)
- South Africa (24)
- Sudan (2)
- Tanzania (6)
- Tunisia (1)
- Uganda (5)
- Zambia (2)
-
- Bangladesh (7)
- China (153)
- Georgia (70)
- India (322)
- Indonesia (10)
- Iran (13)
- Iraq (2)
- Israel (14)
- Japan (55)
- Jordan (4)
- Kazakhstan (1)
- Kuwait (1)
- Laos (1)
- Lebanon (3)
- Malaysia (24)
- Mongolia (2)
- Nepal (2)
- Pakistan (14)
- Philippines (12)
- Qatar (3)
- Saudi Arabia (5)
- Singapore (19)
- South Korea (31)
- Sri Lanka (8)
- Syrian Arab Republic (1)
- Taiwan (11)
- Thailand (13)
- Turkey (10)
- Uzbekistan (2)
- Vietnam (1)
- Yemen (1)
-
- Albania (1)
- Austria (10)
- Belarus (2)
- Belgium (13)
- Bulgaria (1)
- Croatia (3)
- Cyprus (2)
- Czech Republic (8)
- Denmark (13)
- Finland (9)
- France (27)
- Germany (49)
- Greece (7)
- Hungary (1)
- Ireland (22)
- Italy (18)
- Lithuania (6)
- Luxembourg (2)
- Macedonia (1)
- Malta (1)
- Moldova, Republic Of (2)
- Netherlands (23)
- Norway (7)
- Poland (9)
- Portugal (3)
- Romania (9)
- Russian Federation (25)
- Serbia and Montenegro (1)
- Slovenia (1)
- Spain (24)
- Sweden (18)
- Switzerland (20)
- Ukraine (3)
- United Kingdom (124)
-
- Australia (114)
- Austria (10)
- Belgium (13)
- Canada (176)
- Chile (1)
- Czech Republic (8)
- Denmark (13)
- Finland (9)
- France (27)
- Germany (49)
- Greece (7)
- Hungary (1)
- Ireland (22)
- Israel (14)
- Italy (18)
- Japan (55)
- Luxembourg (2)
- Mexico (12)
- Netherlands (23)
- New Zealand (15)
- Norway (7)
- Poland (9)
- Portugal (3)
- Slovenia (1)
- South Korea (31)
- Spain (24)
- Sweden (18)
- Switzerland (20)
- Turkey (10)
- United Kingdom (124)
- United States (1 632)
data types
- All
- Company Data (5 623)
- Industry Data
- Country Data (2 098)
Cancer Drug Market and Forecasts, May 2013
You might be interested in: drug, cancer, clinical trial, more »
industry reports
country reports
Cancer Drug and Drug Industries
- Industry report
- April 2011
- 37 pages
... Light green drugs with special consideration (e.G. Cost-saving, improved patient experience) blue drugs that appear to meet new nice end of life medicines criteria amber drugs with low score ...
- Industries: Drug and Medication
Industry report on Cancer Drug and Drug
- Industry report
- September 2011
- 12 pages
... More of treat to the optimal uptake of new drugs than the issue of budgetary limitations. Though cancer drugs account for ...
- Industries: Drug and Medication
The Indian Cancer Drug and Drug Market : Sectors Brief
- Industry report
- May 2012
- 2 pages
... Treatment as drugs are priced beyond their reach. "This initiative of price reduction is a humanitarian approach by cipla to support cancer patients," company chairman y.K. Hamied said in a statement, which ...
- Industries: Drug and Medication
- Countries: India
U.S. Drug and Medication Business : Innovation and Technology Trends
- Industry report
- April 2013
- 47 pages
... In quality-adjusted life-years is not necessarily less than the increase in life expectancy. Since the lifetime risk of being diagnosed with cancer is about 40%, the 1978-2004 increase in the lagged ...
- Industries: Drug and Medication
- Countries: United States
Pharmaceutical Business Brief
- Industry report
- November 2012
- 2 pages
... Due to artificially low government price caps. In too many cases they must either produce drugs at a loss or pull them from the market. Yes, the medicare modernization act has lowered the cost ...
- Industries: Pharmaceutical
Drug in Germany, Italy and The United States : Innovation and Technology Trends
- Industry report
- March 2012
- 30 pages
... Are now faced with novel antibodies and small molecules, the so-called targeted agents, which are used more and more, in sequence rather than in combination. cancer as a chronic disease ...
- Industries: Drug and Medication
- Countries: Germany, Italy, United States
U.S. Drug Industry Brief
- Industry report
- May 2011
- 4 pages
... Of the drugs on the list For example Doxoru Icin in lymphoma Vincristine in child- hood tumors And leucovorin for colon cancer and as a res- cue agent post high-dose meth- otrexate in childhood tumors ...
- Industries: Drug and Medication
- Countries: United States
Drug Market in The United States
- Industry report
- January 2012
- 2 pages
... For certain drugs caused their price to drop dramatically. For example, the cancer drug paclitaxel fell in price by an order of magnitude, from $2,272 per dose to $225 per dose, over the course of a month ...
- Industries: Drug and Medication
- Countries: United States
Drug and Medication Industry in Europe and The United States
- Industry report
- February 2012
- 10 pages
... Major drugs european authorities have approved astrazeneca's new thyroid cancer pill caprelsa, or vandetanib, confirming its position as a niche treatment for some patients. The green light from ...
- Industries: Drug and Medication
- Countries: Europe, United Kingdom, United States
Drug in The United States : Industry Overview and Key Players
- Industry report
- October 2012
- 16 pages
... T the new brand-name therapies but are instead the decades-old cancer drugs, anesthetic agents, and other generic injectable drugs that cost as little as $1 per vial.4 Why has the number of drug shortages ...
- Industries: Drug and Medication
- Countries: United States
» Purchase Premium Reports (From $ 125 - $ 12 375)
About 500 reports for Cancer Drug
Drug and Medication in United States: Colon Cancer - Pipeline Review, H1 2012
- $ 2 000
- Industry report
- February 2013
- by Global Markets Direct
This report provides information on the therapeutic development for Colon Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...
» Read our Company Profiles
7 Companies for Cancer DrugAccessEd
AustraliaBig Island Tropical Flower Farms
United StatesCitrix
United StatesAccountABLE Consulting L.L.C.
United StatesBritish American Tobacco
SpainReportlinker.com © Copyright 2013. All rights reserved.
